Pediatrix Medical Group, Inc. (MD)
| Market Cap | 1.89B +75.7% |
| Revenue (ttm) | 1.93B -2.3% |
| Net Income | 174.22M |
| EPS | 2.06 |
| Shares Out | 80.19M |
| PE Ratio | 11.39 |
| Forward PE | 10.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 798,764 |
| Open | 23.04 |
| Previous Close | 22.93 |
| Day's Range | 22.91 - 23.74 |
| 52-Week Range | 11.84 - 24.99 |
| Beta | 0.71 |
| Analysts | Hold |
| Price Target | 20.50 (-12.8%) |
| Earnings Date | May 5, 2026 |
About MD
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. The company offers clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through its network of affiliated neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; and inpatient and office-based clinical care to expectant mothers and unborn babies through its affiliated maternal-fe... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for MD stock is "Hold." The 12-month stock price target is $20.5, which is a decrease of -12.80% from the latest price.
News
Pediatrix Medical price target raised to $24 from $21 at Mizuho
Mizuho raised the firm’s price target on Pediatrix Medical (MD) to $24 from $21 and keeps a Neutral rating on the shares.
Pediatrix Medical Group Earnings Call Transcript: Q1 2026
Strong Q1 results featured robust pricing and adjusted EBITDA of $58M, with revenue growth from acquisitions and favorable payer mix. Full-year adjusted EBITDA guidance of $280M–$300M is reaffirmed, and pricing is expected to moderate as the year progresses.
Pediatrix Medical reaffirms FY26 adjusted EBITDA view $280M-$300M
06:10 EDT Pediatrix Medical (MD) reaffirms FY26 adjusted EBITDA view $280M-$300M
Pediatrix Medical Group Reports First Quarter Results
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group Reports First Quarter Results.
Ambience Healthcare Appoints Michael Han, MD, MBA as Chief Medical Officer
SAN FRANCISCO--(BUSINESS WIRE)--Ambience Healthcare, the leading AI platform for clinical documentation and revenue integrity, today announced the appointment of Michael Han, MD, MBA as Chief Medical ...
Pediatrix Medical price target raised to $27 from $24 at Jefferies
Jefferies analyst Jack Slevin raised the firm’s price target on Pediatrix Medical (MD) to $27 from $24 and keeps a Buy rating on the shares. The relative underperformance of healthcare
Pediatrix Medical Group 2026 First Quarter Conference Call/Webcast Scheduled for Tuesday, May 5, 2026
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group 2026 First Quarter Conference Call/Webcast Scheduled for Tuesday, May 5, 2026.
Pediatrix Medical price target raised to $23 from $21 at Truist
Truist raised the firm’s price target on Pediatrix Medical (MD) to $23 from $21 and keeps a Hold rating on the shares as part of a broader research note previewing
Pediatrix Expands Maternal Health Services in Tennessee in Partnership with Tennessee Maternal-Fetal Medicine
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Expands Maternal Health Services in Tennessee in Partnership with Tennessee Maternal-Fetal Medicine.
Pediatrix Welcomes Two Nationally Renowned Physician Leaders
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Welcomes Two Nationally Renowned Physician Leaders.
Pediatrix Medical price target lowered to $22 from $23 at UBS
UBS analyst AJ Rice lowered the firm’s price target on Pediatrix Medical (MD) to $22 from $23 and keeps a Neutral rating on the shares. The ACA headwind remains a
Pediatrix Medical Group Announces 47th Annual NEO: The Conference for Neonatology
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group Announces 47th Annual NEO: The Conference for Neonatology.
Pediatrix Medical price target lowered to $19 from $21 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Pediatrix Medical (MD) to $19 from $21 and keeps a Hold rating on the shares. The firm says the company’s volumes were
Pediatrix Medical price target lowered to $21 from $24 at Truist
Truist lowered the firm’s price target on Pediatrix Medical (MD) to $21 from $24 and keeps a Hold rating on the shares. The firm maintained its Hold view following Q4
Pediatrix Medical Group Earnings Call Transcript: Q4 2025
Q4 2025 capped a strong year with adjusted EBITDA of $66M and full-year $276M, driven by favorable payer mix, acuity, and disciplined cost control. 2026 guidance projects flat revenue at $1.9B and 5% EBITDA growth, with steady operational metrics and no M&A included.
Pediatrix Medical sees FY26 adjusted EBITDA $280M-$300M
06:12 EST Pediatrix Medical (MD) sees FY26 adjusted EBITDA $280M-$300M
Pediatrix Medical Group Reports Fourth Quarter Results
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group Reports Fourth Quarter Results.
Pediatrix Medical Group 2025 Fourth Quarter Conference Call/Webcast Scheduled for Thursday, February 19, 2026
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group 2025 Fourth Quarter Conference Call/Webcast Scheduled for Thursday, February 19, 2026.
Pediatrix Medical price target raised to $24 from $17 at Truist
Truist analyst David MacDonald raised the firm’s price target on Pediatrix Medical (MD) to $24 from $17 and keeps a Hold rating on the shares. The firm is updating its
Pediatrix Medical price target raised to $23 from $16.50 at UBS
UBS raised the firm’s price target on Pediatrix Medical (MD) to $23 from $16.50 and keeps a Neutral rating on the shares. Pricing growth drove a strong Q3, and UBS
Pediatrix Medical Group Earnings Call Transcript: Q3 2025
Adjusted EBITDA for Q3 2025 exceeded expectations at $87 million, driven by strong pricing, collections, and expense controls. Portfolio restructuring and acquisitions enhanced focus and performance, while full-year adjusted EBITDA guidance is set at $270–$290 million.
Pediatrix Medical Group Reports Third Quarter Results
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group Reports Third Quarter Results; Raises Full Year 2025 Adjusted EBITDA Outlook Range.
Pediatrix Medical Group 2025 Third Quarter Conference Call/Webcast Scheduled for Monday, November 3, 2025
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group 2025 Third Quarter Conference Call/Webcast Scheduled for Monday, November 3, 2025.
Pediatrix Medical price target raised to $17 from $16 at Truist
Truist analyst David MacDonald raised the firm’s price target on Pediatrix Medical (MD) to $17 from $16 and keeps a Hold rating on the shares as part of a broader
Pediatrix Medical announces $250M share repurchase program
Pediatrix Medical (MD) Group announced that its Board of Directors has authorized a share repurchase program of up to $250M of the Company’s outstanding common stock. “In view of our